Mesoblast (MSB) - Waiting for readouts

Edison Investment Research - Pharmaceutical & healthcare - Mesoblast: Mesoblast is entering a period of top-line readouts. This note focuses on two possible value events in 2018 in graft vs host disease and in Class IV heart failure. In addition, the critical Phase III heart failure (HF) trial could complete enrolment in H218; the trial readout depends on the number and timing of clinical events but will probably not be before H219. The lower back pain trial plans to complete enrolment by the end of 2017 with a two-year endpoint. Mesoblast had effective cash of US$84.0m on 30 June.
ISIN: AU000000MSB8

Original Article: Mesoblast (MSB) - Waiting for readouts

More From BioPortfolio on "Mesoblast (MSB) - Waiting for readouts"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications